12/4
10:58 am
tech
Bio-Techne Corporation (TECH): A Bull Case Theory [Yahoo! Finance]
Low
Report
Bio-Techne Corporation (TECH): A Bull Case Theory [Yahoo! Finance]
11/28
11:26 pm
tech
Bio-Techne (TECH): Evaluating Valuation After ACA Subsidy Extension Boosts Market Sentiment [Yahoo! Finance]
Low
Report
Bio-Techne (TECH): Evaluating Valuation After ACA Subsidy Extension Boosts Market Sentiment [Yahoo! Finance]
11/25
07:50 am
tech
Bio-Techne to Present at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Bio-Techne to Present at Upcoming Investor Conferences [Yahoo! Finance]
11/25
07:00 am
tech
Bio-Techne to Present at Upcoming Investor Conferences
Medium
Report
Bio-Techne to Present at Upcoming Investor Conferences
11/21
02:33 am
tech
Exclusive AI-Designed Protein Access Might Change the Case for Investing in Bio-Techne (TECH) [Yahoo! Finance]
Low
Report
Exclusive AI-Designed Protein Access Might Change the Case for Investing in Bio-Techne (TECH) [Yahoo! Finance]
11/20
09:58 am
tech
Bio-Techne Corporation (TECH) Presents at Jefferies London Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
Bio-Techne Corporation (TECH) Presents at Jefferies London Healthcare Conference 2025 Transcript [Seeking Alpha]
11/20
09:21 am
tech
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Argus from $65.00 to $68.00. They now have a "buy" rating on the stock.
Low
Report
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Argus from $65.00 to $68.00. They now have a "buy" rating on the stock.
11/18
04:44 pm
tech
Bio-Techne Corporation (TECH) Presents at Stephens Annual Investment Conference 2025 Transcript [Seeking Alpha]
Low
Report
Bio-Techne Corporation (TECH) Presents at Stephens Annual Investment Conference 2025 Transcript [Seeking Alpha]
11/18
07:05 am
tech
Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio [Yahoo! Finance]
Low
Report
Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio [Yahoo! Finance]
11/18
06:30 am
tech
Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio
Low
Report
Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio
11/14
02:34 am
tech
Bio-Techne Stock: Is Wall Street Bullish or Bearish? [Yahoo! Finance]
Low
Report
Bio-Techne Stock: Is Wall Street Bullish or Bearish? [Yahoo! Finance]
11/13
09:15 am
tech
Is Bio-Techne Corporation (TECH) a High-Quality Growth-Oriented Compounder Within The Healthcare Sector? [Yahoo! Finance]
Low
Report
Is Bio-Techne Corporation (TECH) a High-Quality Growth-Oriented Compounder Within The Healthcare Sector? [Yahoo! Finance]
11/12
04:12 pm
tech
Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 [Yahoo! Finance]
Low
Report
Mdxhealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2025 [Yahoo! Finance]
11/11
04:10 pm
tech
Bio-Techne, Tandem Diabetes, Align Technology, DexCom, and Teleflex Shares Skyrocket, What You Need To Know [Yahoo! Finance]
Low
Report
Bio-Techne, Tandem Diabetes, Align Technology, DexCom, and Teleflex Shares Skyrocket, What You Need To Know [Yahoo! Finance]
11/10
01:03 pm
tech
Bio-Techne Corporation (TECH) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Low
Report
Bio-Techne Corporation (TECH) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/9
01:23 am
tech
McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. [Yahoo! Finance]
Low
Report
McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. [Yahoo! Finance]
11/6
04:00 pm
tech
Bio-Techne (NASDAQ:TECH) was given a new $68.00 price target on by analysts at Evercore ISI.
Low
Report
Bio-Techne (NASDAQ:TECH) was given a new $68.00 price target on by analysts at Evercore ISI.
11/6
01:29 pm
tech
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at UBS Group AG from $65.00 to $70.00. They now have a "buy" rating on the stock.
Low
Report
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at UBS Group AG from $65.00 to $70.00. They now have a "buy" rating on the stock.
11/6
10:50 am
tech
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Wells Fargo & Company from $59.00 to $70.00. They now have an "overweight" rating on the stock.
Low
Report
Bio-Techne (NASDAQ:TECH) had its price target raised by analysts at Wells Fargo & Company from $59.00 to $70.00. They now have an "overweight" rating on the stock.
11/6
07:00 am
tech
Bio-Techne to Present at Upcoming Investor Conferences
Medium
Report
Bio-Techne to Present at Upcoming Investor Conferences
11/5
06:30 am
tech
Bio-Techne Releases First Quarter Fiscal 2026 Results
Medium
Report
Bio-Techne Releases First Quarter Fiscal 2026 Results
11/5
06:30 am
tech
BIO-TECHNE DECLARES DIVIDEND
Medium
Report
BIO-TECHNE DECLARES DIVIDEND
11/4
09:01 am
tech
AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
Low
Report
AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma Patients
11/3
07:00 am
tech
ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics
Low
Report
ScaleReady Announces a G-Rex® Grant has been awarded to Sonoma Biotherapeutics
10/28
06:30 am
tech
Bio-Techne Launches ProximityScope™ Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research
Medium
Report
Bio-Techne Launches ProximityScope™ Assay on the BOND RX platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions Research